InsiderTrades.com logo
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

INM Insider Trading

Insider Ownership Percentage: 2.30%
Insider Buying (Last 12 Months): $7,276.00
Insider Selling (Last 12 Months): $0.00

InMed Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at InMed Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

InMed Pharmaceuticals Share Price & Price History

Current Price: $1.31
Price Change: ▼ Price Decrease of -0.25 (-16.03%)
As of 03/24/2023 01:00 AM ET

This chart shows the closing price history over time for INM up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

InMed Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/13/2022Eric A. AdamsCEOBuy8,560$0.85$7,276.0044,843View SEC Filing Icon  
1/24/2022Bruce S. ColwillCFOBuy5,000$1.09$5,450.00View SEC Filing Icon  
1/6/2022Shane Aaron JohnsonSVPBuy8,500$1.26$10,710.00View SEC Filing Icon  
12/30/2021Shane Aaron JohnsonSVPBuy8,093$1.33$10,763.69View SEC Filing Icon  
11/15/2021Shane Aaron JohnsonSVPBuy5,000$1.37$6,850.00View SEC Filing Icon  
9/28/2021Bruce S. ColwillCFOBuy5,000$1.77$8,850.00View SEC Filing Icon  
9/28/2021Eric A. AdamsCEOBuy11,400$1.75$19,950.00View SEC Filing Icon  
See Full Table
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel

SEC Filings (Institutional Ownership Changes) for InMed Pharmaceuticals (NASDAQ:INM)

14.31% of InMed Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at INM by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

InMed Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
2/15/2023Virtu Financial LLC17,724$36K0.0%N/A1.886%Search for SEC Filing on Google Icon
2/15/2023Armistice Capital LLC97,163$0.20M0.0%+8.0%10.336%Search for SEC Filing on Google Icon
11/14/2022Armistice Capital LLC90,000$0.59M0.0%-90.6%9.605%Search for SEC Filing on Google Icon
11/10/2022UBS Group AG5,797$38K0.0%N/A0.617%Search for SEC Filing on Google Icon
5/17/2022Empery Asset Management LP61,741$58K0.3%N/A0.437%Search for SEC Filing on Google Icon
8/17/2021Armistice Capital LLC890,000$2.83M0.1%+278.7%9.954%Search for SEC Filing on Google Icon
8/12/2021Penserra Capital Management LLC19,912$49K0.0%N/A0.223%Search for SEC Filing on Google Icon
5/21/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214%Search for SEC Filing on Google Icon
5/18/2021Citadel Advisors LLC17,211$57K0.0%N/A0.214%Search for SEC Filing on Google Icon
5/17/2021Armistice Capital LLC235,000$0.78M0.0%N/A2.919%Search for SEC Filing on Google Icon
1/29/2021Creative Planning10,990$36K0.0%N/A0.157%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
InMed Pharmaceuticals logo
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. The company's prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. Its lead product is INM-755, a cannabinol topical skin cream, which is in Phase 2 clinical trial for the treatment of epidermolysis bullosa. The company is also developing INM-088, which is in preclinical studies for the treatment of glaucoma; INM-405 for the treatment of pain; and cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. In addition, it offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Read More on InMed Pharmaceuticals

Today's Range

Now: $1.31
Low: $1.25
High: $1.57

50 Day Range

MA: $1.59
Low: $1.05
High: $2.20

52 Week Range

Now: $1.31
Low: $0.92
High: $35.50

Volume

298,590 shs

Average Volume

1,587,157 shs

Market Capitalization

$4.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of InMed Pharmaceuticals?

InMed Pharmaceuticals' top insider investors include:
  1. Eric A Adams (CEO)
  2. Bruce Colwill (CFO)
  3. Shane Aaron Johnson (SVP)
Learn More about top insider investors at InMed Pharmaceuticals.

Who are the major institutional investors of InMed Pharmaceuticals?

InMed Pharmaceuticals' top institutional investors include:
  1. Armistice Capital LLC — 10.34%
  2. Virtu Financial LLC — 1.89%
Learn More about top institutional investors of InMed Pharmaceuticals stock.

Which institutional investors are buying InMed Pharmaceuticals stock?

Within the last quarter, INM stock was acquired by institutional investors including:
  1. Virtu Financial LLC
  2. Armistice Capital LLC
In the last year, these company insiders have bought InMed Pharmaceuticals stock:
  1. Eric A Adams (CEO)
  2. Bruce Colwill (CFO)
  3. Shane Aaron Johnson (SVP)
Learn More investors buying InMed Pharmaceuticals stock.
The Safest Option in Trades!
From Tradewins   |   Ad
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!
pixel